Gene Express Signs Strategic Agreement With VWR International

Gene Express, Inc. today announced that it has signed a strategic agreement with VWR International, Inc. to resell and distribute Gene Express' SEM Center(TM) (Standardized Expression Measurement) services to biotech and pharmaceutical companies as well as clinical research organizations (CROs).

Gene Express's SEM Center(TM) process is a high throughput gene expression assay process using automated equipment and proprietary software that ensures that all assays are setup, performed and analyzed with minimal human intervention. The SEM Center uses Gene Express's proprietary StaRT-PCR(TM) (Standardized Reverse Transcriptase Polymerase Chain Reaction) process to provide quantitative, reproducible, sensitive, standardized gene expression measurement.

The three-year North American agreement gives VWR a strong gene expression addition to its Bioscience service portfolio, while offering Gene Express the strength and reach of VWR's sales organization.

"We are very pleased to be working with VWR," stated Gerald Vardzel, CEO of Gene Express. "This agreement represents an important endorsement of our technology and services, which now will gain exposure to a larger customer base. VWR is well positioned in the markets we are pursuing and we look forward to a fruitful relationship."

"Quantification of gene expression is critical to targeted therapeutics and diagnostics," noted Dr. Zishan Haroon M.D., Ph.D., General Manager and Senior Vice President of VWR Bioscience. "Gene Express provides a service that not only quantifies gene expression, but does so under FDA guidance characteristics. We are delighted to have Gene Express as part of our CRO platform and are confident that customers will share our enthusiasm and excitement about their offering."

"Our strategy is to partner with market leading companies such as VWR, that are on the forefront of innovation," added Mr. Vardzel.

As part of the agreement, Gene Express presented at the first annual VWR BioSciences Sales Meeting in Santa Fe, New Mexico, where the team described its StaRT-PCR(TM) technology and related SEM Center(TM) services, the differentiating value of StaRT-PCR(TM) data and the target market.

About VWR International

VWR International, Inc. is a leader in the global research laboratory industry with worldwide sales of over US $3.0 billion. VWR's business is highly diversified across a spectrum of products and services, customer groups and geography. The company offers more than 1,000,000 products and services, from more than 5,000 manufacturers, to over 250,000 customers throughout the world. VWR's primary customers work in the pharmaceutical, life science, chemical, technology, food processing and consumer product industries. Other important customers include universities and research institutes; governmental agencies; environmental testing organizations; and primary and secondary schools. VWR International affiliates operate in 20 countries and employ approximately 6,000 people. The company's mission is to deliver excellence in the distribution of scientific supplies. The VWR International Group is headquartered in West Chester, Pennsylvania. For more information about VWR visit the VWR web site at www.vwr.com.

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR(TM) (Standardized Reverse Transcriptase Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, tissue and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at www.geneexpressinc.com.

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Distributed by Market Wire